What are the best healthcare stocks for value investors?

Xeris Biopharma Holdings, Inc. (XERS) currently leads the healthcare sector on the Peter Lynch framework with a composite score of 84/100, followed by ADMA (82/100). The full ranked list of 25 healthcare stocks indexed against the framework is on this page. Educational only, not investment advice.

Which healthcare stock has the highest Buffett-Fit score?

According to invest-like.com, Xeris Biopharma Holdings, Inc. (XERS) currently has the highest Buffett-Fit composite score in the healthcare sector at 84/100. invest-like.com's Buffett-Fit Score weighs five pillars - economic moat, earnings durability, management quality, financial health, and valuation - each on a 0-100 sub-scale, and refreshes the cached verdict on a 7-day TTL.

Is healthcare a good sector for Peter Lynch-style investing?

The healthcare sector's median quality score on invest-like.com is 71/100 with a median ROIC of 16%. Whether healthcare is "good" for Peter Lynch-style investing depends on which sub-sectors and specific stocks you focus on - the framework's sector-relative scoring means stocks are graded against their own sector benchmarks, not a fixed cross-market hurdle.

Which healthcare stocks have the best moats?

invest-like.com anchors moat strength in the Buffett-Fit framework on ROIC sustainability (above 15% sustained over multiple years) plus gross-margin durability (above 40% in industries where peers sit lower). The healthcare sector's median ROIC on invest-like.com is 16% - the top-scoring stocks on this page are the ones with both quantitative moat anchors clearing the threshold AND qualitative moat sources (brand, switching costs, network effects, regulatory).

How many healthcare stocks does invest-like.com cover?

invest-like.com currently indexes 25 healthcare stocks above $500M market cap with cached verdicts on the Buffett-Fit framework. invest-like.com grades each stock A+ to D on a composite 0-100 score, with sub-scores for moat, durability, management, financial health, and valuation. The full ranked list is on this page.

Is the healthcare ranking on this page investment advice?

No. invest-like.com publishes the ranking as an educational pattern-match against documented value-investing frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith). invest-like.com's scores reflect how closely each stock fits the documented criteria - they are NOT recommendations to buy, hold, or sell. Always do your own research and consult a licensed financial adviser for personalised investment advice.

Healthcare · Peter Lynch fit

Best Healthcare Stocks for Peter Lynch Investors

Top 25 healthcare stocks ranked by their Peter Lynch fit score - every score computed from current financials against published criteria. Updated daily.

How We Rank These

Each stock is scored on a 0–100 scale across the Peter Lynch criteria (moat, durability, valuation, financial health, capital allocation). The score is a deterministic function of the company's TTM financials - no opinion, no hand-tuning. Rows with insufficient data are excluded.

The Top 25

#1
84/100
XERSXeris Biopharma Holdings, Inc.C
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$1.36B
ROIC
12.84%
#2
82/100
ADMAADMA Biologics, Inc.C
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$2.07B
ROIC
27.81%
#3
81/100
AUPHAurinia Pharmaceuticals Inc.A
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$2.14B
ROIC
18.99%
#4
79/100
ALNYAlnylam Pharmaceuticals, Inc.B
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$33.28B
ROIC
19.66%
#5
77/100
APLSApellis Pharmaceuticals, Inc.C
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$5.25B
ROIC
18.11%
#6
77/100
LLYEli Lilly and CompanyB
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$994.49B
ROIC
34.84%
#7
77/100
KLACKLA CorporationB
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$236.01B
ROIC
37.17%
#8
76/100
AMGNAmgen Inc.B
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$204.01B
ROIC
15.02%
#9
76/100
IRMDIRadimed CorporationB
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$1.05B
ROIC
21.38%
#10
73/100
LNTHLantheus Holdings, Inc.B
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$6.55B
ROIC
10.75%
#11
71/100
ISRGIntuitive Surgical, Inc.B
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$132.26B
ROIC
13.39%
#12
71/100
ACADACADIA Pharmaceuticals Inc.B
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$4.77B
ROIC
6.17%
#13
71/100
INDVIndivior Pharmaceuticals IncB
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$4.07B
ROIC
85.68%
#14
71/100
IDXXIDEXX Laboratories, Inc.B
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$39.81B
ROIC
40.66%
#15
69/100
ONCBeOne Medicines Ltd.B
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$39.2B
ROIC
7.73%
#16
68/100
VCYTVeracyte, Inc.B
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$3.29B
ROIC
4.73%
#17
67/100
INSPInspire Medical Systems, Inc.B
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$2.11B
ROIC
6.24%
#18
66/100
MTDMettler-Toledo International Inc.B
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$25.92B
ROIC
36.09%
#19
65/100
CPRXCatalyst Pharmaceuticals, Inc.B
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$3.85B
ROIC
19.67%
#20
65/100
MEDPMedpace Holdings, Inc.B
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$16.4B
ROIC
56.06%
#21
65/100
AVAHAveanna Healthcare Holdings Inc.B
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$3.07B
ROIC
15.86%
#22
65/100
ANIPANI Pharmaceuticals, Inc.C
Strong GARP candidate - growth at a reasonable price.
Mkt cap
$1.61B
ROIC
8.17%
#23
64/100
ALHCAlignment Healthcare, Inc.C
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$2.62B
ROIC
5.88%
#24
63/100
LMATLeMaitre Vascular, Inc.C
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$1.84B
ROIC
9.43%
#25
63/100
NBIXNeurocrine Biosciences, Inc.C
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$15.88B
ROIC
13.68%

Same Sector, Other Strategies

Best Healthcare for Warren Buffett Best Healthcare for Benjamin Graham Best Healthcare for Joel Greenblatt